ATE218875T1 - Eisen-dextran formulierungen - Google Patents

Eisen-dextran formulierungen

Info

Publication number
ATE218875T1
ATE218875T1 AT96930686T AT96930686T ATE218875T1 AT E218875 T1 ATE218875 T1 AT E218875T1 AT 96930686 T AT96930686 T AT 96930686T AT 96930686 T AT96930686 T AT 96930686T AT E218875 T1 ATE218875 T1 AT E218875T1
Authority
AT
Austria
Prior art keywords
iron dextran
dextran formulations
formulations
daltons
molecular weight
Prior art date
Application number
AT96930686T
Other languages
English (en)
Inventor
Richard P Lawrence
Ralf A Lange
Mary Jane Helenek
Chin Wu
Original Assignee
Luitpold Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luitpold Pharm Inc filed Critical Luitpold Pharm Inc
Application granted granted Critical
Publication of ATE218875T1 publication Critical patent/ATE218875T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT96930686T 1995-09-29 1996-08-29 Eisen-dextran formulierungen ATE218875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,984 US5624668A (en) 1995-09-29 1995-09-29 Iron dextran formulations
PCT/US1996/014153 WO1997011711A1 (en) 1995-09-29 1996-08-29 Iron dextran formulations

Publications (1)

Publication Number Publication Date
ATE218875T1 true ATE218875T1 (de) 2002-06-15

Family

ID=24140716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930686T ATE218875T1 (de) 1995-09-29 1996-08-29 Eisen-dextran formulierungen

Country Status (11)

Country Link
US (1) US5624668A (de)
EP (1) EP0855913B1 (de)
JP (1) JP3471363B2 (de)
AT (1) ATE218875T1 (de)
AU (1) AU702691B2 (de)
CA (1) CA2184551C (de)
DE (1) DE69621813T2 (de)
DK (1) DK0855913T3 (de)
ES (1) ES2179207T3 (de)
PT (1) PT855913E (de)
WO (1) WO1997011711A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306384B1 (en) * 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
US6610206B1 (en) 1998-10-20 2003-08-26 Advanced Renal Technologies Buffered compositions for dialysis
US7670491B2 (en) * 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
WO2001021233A1 (en) * 1999-09-22 2001-03-29 Advanced Renal Technologies High citrate dialysate and uses thereof
EP1330226A4 (de) * 2000-11-02 2005-11-23 Chromaceutical Advanced Tech Verfahren zur herstellung eines gereinigten hämatin-eisen-saccharid-komplexes und hergestelltes produkt
US6929954B2 (en) * 2000-11-02 2005-08-16 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
EP1719496A3 (de) * 2000-11-02 2007-05-16 Chromaceutical Advanced Technologies, Inc. Verfahren zur Herstellung eines gereinigten Hämatin-Eisen-Saccharid-Komplexes und hergestelltes Produkt
US6825032B2 (en) * 2001-05-14 2004-11-30 Sigma-Aldrich Co. High capacity assay platforms
EP1540338B1 (de) * 2002-08-26 2008-10-08 Vifor (International) Ag Bioäquivalenztest für eisenhaltige formulierungen
US7169359B2 (en) * 2002-08-26 2007-01-30 Luitpold Pharmaceuticals, Inc. Bioequivalence test for iron-containing formulations
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US7390472B1 (en) * 2002-10-29 2008-06-24 Nei Corp. Method of making nanostructured lithium iron phosphate—based powders with an olivine type structure
US20040161852A1 (en) * 2003-02-14 2004-08-19 Anderson Christopher G. Method of assaying an Fe-Sugar complex
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
WO2006017179A1 (en) 2004-07-09 2006-02-16 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
PT1973549T (pt) 2006-01-06 2016-10-25 Luitpold Pharm Inc Métodos e composições para administração de ferro
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080132465A1 (en) * 2006-12-05 2008-06-05 Vincent Windisch Apparatus and method for isolating iron components from serum
EP2123270B2 (de) * 2006-12-12 2016-06-15 Advanced Renal Technologies, Inc. Mittel zur verbesserung des eisenstoffwechsels
TWI468167B (zh) 2007-11-16 2015-01-11 威佛(國際)股份有限公司 藥學組成物
EP2411053B1 (de) 2009-03-25 2016-11-30 Pharmacosmos Holding A/s Stabile eisen-oligosaccharid-verbindung
US8058076B2 (en) * 2009-03-31 2011-11-15 Astron Research Limited In-vitro method for testing bioequivalence of iron-sucrose formulation
PT104879B (pt) * 2009-12-10 2012-10-17 Univ Do Minho Hidrogel de dextrino para aplicações biomédicas
CN103044571A (zh) * 2011-10-13 2013-04-17 天津中敖生物科技有限公司 右旋糖酐铁原料药及其制备方法
JP6189309B2 (ja) 2011-10-13 2017-08-30 ヴィダシム・インコーポレーテッド 鉄−繊維組成物、その調製および使用
AU2014226059B9 (en) * 2013-03-08 2018-05-10 Alebund Pharmaceuticals (Hong Kong) Limited Metal ion-functional fiber component complex compositions, preparation and uses thereof
US9370202B2 (en) * 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
WO2018198135A1 (en) * 2017-04-26 2018-11-01 Mylan Laboratories Ltd. Improved process for the preparation of iron complex
AU2018328052C1 (en) 2017-09-11 2025-12-18 Pharmacosmos Holding A/S Iron complex compounds for therapeutic use
AU2018381338B2 (en) * 2017-12-07 2022-12-08 Commonwealth Scientific And Industrial Research Organisation Sugar reduced products and method of producing thereof
CN119488480A (zh) 2019-02-28 2025-02-21 雷尼布斯治疗公司 新型铁组合物及其制造和使用方法
CN113567370A (zh) * 2021-07-23 2021-10-29 广西南宁市桃源兽药厂 一种用于检测右旋糖酐铁注射液中糖酐含量的方法
CN116712455B (zh) * 2023-06-30 2024-04-05 重庆汉佩生物科技有限公司 一种氟苯尼考与葡庚糖酐铁的组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) * 1959-04-28 Therapeutic preparations of iron
US2820740A (en) * 1953-02-27 1958-01-21 Benger Lab Ltd Therapeutic preparations of iron
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3697502A (en) * 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3686397A (en) * 1970-05-18 1972-08-22 Mueller Arthur Parenteral iron preparations
US3908004A (en) * 1970-05-20 1975-09-23 C L Basingstoke Limited Process for making injectable iron compositions for treating iron-deficiency anemia
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
DE3026868C2 (de) * 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4454773A (en) * 1981-11-06 1984-06-19 Texaco Inc. Time interval automatic well multi-phase fluid sampler
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
JPS58199018A (ja) * 1982-05-18 1983-11-19 Nippon Denso Co Ltd 電気的加熱手段を有する排気ガス微粒子浄化装置
US4659697A (en) * 1983-05-20 1987-04-21 Kentaro Tanaka Antianaemic composition and a process for producing the same
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5248492A (en) * 1986-07-03 1993-09-28 Advanced Magnetics, Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5336506A (en) * 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
US5118513A (en) * 1987-07-02 1992-06-02 The Procter & Gamble Company Method for enhancing bioavailability of iron-calcium mineral supplements
US5354350A (en) * 1993-12-14 1994-10-11 The Vigoro Corporation Citrate soluble slow release iron humate

Also Published As

Publication number Publication date
PT855913E (pt) 2002-11-29
US5624668A (en) 1997-04-29
EP0855913B1 (de) 2002-06-12
AU6964796A (en) 1997-04-17
DK0855913T3 (da) 2002-10-07
EP0855913A1 (de) 1998-08-05
JPH11512706A (ja) 1999-11-02
ES2179207T3 (es) 2003-01-16
DE69621813D1 (de) 2002-07-18
CA2184551A1 (en) 1997-03-30
CA2184551C (en) 2001-11-27
WO1997011711A1 (en) 1997-04-03
DE69621813T2 (de) 2003-01-23
AU702691B2 (en) 1999-03-04
EP0855913A4 (de) 1999-01-20
JP3471363B2 (ja) 2003-12-02

Similar Documents

Publication Publication Date Title
DK0855913T3 (da) Jern-dextran-formuleringer
TW368504B (en) Modified arginine deiminase
IL133890A0 (en) Trifluoroacetyl copolymer - 1
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG104943A (en) Biodegradable sustained-release alginate gels
MY121031A (en) Process for preparing derivatives of the taxoid family
KR880700668A (ko) 특정 생체조직 부위로의 전달을 위한 아미노산 킬레이트의 조성물
MXPA01007710A (es) Agente de secado por congelacion que contiene paramilon, su produccion y uso.
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
PL364861A1 (en) Coating composition comprising an oxidatively drying polyunsaturated condensation product, a polythiol, and a siccative
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
NZ225770A (en) Compositions of substituted 1,2,3-triazoles
DE69633178D1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
TW349000B (en) Fungicidal two-component composition based on R-metalaxyl and usage thereof
BG102667A (en) Diosgenine-containing composition
DK0921793T3 (da) Faste, ikke-henflydende formuleringer af natriumvalproat
BG100248A (bg) Инхибитори на скваленсинтетаза
IT1304497B1 (it) Composizione polimerica ad elevata trasparenza.
BR9609114A (pt) Composição inseticida de terra diatomácea
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
EP0812192A4 (de) Benzothiopyranoindazole als arzneimittel
ATE229315T1 (de) Zusammensetzungen enthaltend filmbildende schweisshemmende polymere
DE60212101D1 (de) Alanin-2,6-dialkoxyphenylesterderivate als hypnotika
MX9604132A (es) Composiciones cosmeticas en polvo.
MY113485A (en) Carbon blacks

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner